Preeclampsia: the role of the terminal complement pathway in early diagnosis and targeted therapy: a review
V.F.Snegirev Archives of Obstetrics and Gynecology · 14.11.2026 · 13 (3) · 238-247
DOI: 10.17816/aog708385 ↗Kurz gefasst
Fachartikel in der Zeitschrift V.F.Snegirev Archives of Obstetrics and Gynecology, online erschienen am 14.11.2026. Verfasst von Aida E. Akhmedova und 7 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben.
Abstract (Originalsprache)
Preeclampsia remains a leading cause of maternal and perinatal mortality, affecting approximately 4 million pregnant women worldwide annually. The lack of reliable early predictors and pathogenetically substantiated therapy necessitates in-depth study of the molecular mechanisms of the disease, among which dysregulation of the complement system occupies a special place. This review systematizes current data on the contribution of the terminal complement activation pathway to preeclampsia development. The formation of the membrane attack complex (MAC) C5b-9 on the endothelium and trophoblast triggers a cascade of proinflammatory reactions with release of the antiangiogenic factor sFlt-1, closing the vicious cycle of placental ischemia. Plasma levels of soluble sC5b-9 begin to increase at 11–14 weeks of gestation, preceding clinical symptoms by several months. Urinary excretion of C5b-9 shows high specificity: at concentrations ≥ 22 ng/mL, the risk of severe preeclampsia increases 10-fold, exceeding the diagnostic value of plasma tests. Immunohistochemical analysis of placentas revealed a twofold increase in C5b-9 deposition in preeclampsia compared with physiological pregnancy, predominantly in decidual vessels. C5a and MAC levels correlate with the severity of placental insufficiency: at MAC ≥ 2717 mAU/mL, fetal growth restriction is predicted with 61% sensitivity and 82% specificity. Methodological limitations of complement component measurement are analyzed, including ex vivo activation and the need to use EDTA tubes for sample stabilization. The article describes the molecular mechanisms of the terminal complement cascade in preeclampsia, presents diagnostic threshold values of C5a and sC5b-9 for clinical application, their correlation with Doppler ultrasound and angiogenic markers, and a scientific basis for developing anticomplement therapy with C5-component inhibitors in obstetric practice.
Zitieren
APA
Akhmedova, A. E., Timokhina, E. V., Ignatko, I. V., Sarakhova, D. K., Belousova, V. S., Fedyunina, I. A., Bogomazova, I. M., & Kardanova, M. A. (2026). Preeclampsia: the role of the terminal complement pathway in early diagnosis and targeted therapy: a review. V.F.Snegirev Archives of Obstetrics and Gynecology, 13(3), 238-247. https://doi.org/10.17816/aog708385
Vancouver
Akhmedova AE, Timokhina EV, Ignatko IV, Sarakhova DK, Belousova VS, Fedyunina IA, et al. Preeclampsia: the role of the terminal complement pathway in early diagnosis and targeted therapy: a review. V.F.Snegirev Archives of Obstetrics and Gynecology. 2026;13(3):238-247. doi:10.17816/aog708385
BibTeX
@article{Akhmedova2026,
author = {Akhmedova, Aida E. and Timokhina, Elena V. and Ignatko, Irina V. and Sarakhova, Dzhamilya Kh. and Belousova, Vera S. and Fedyunina, Irina A. and Bogomazova, Irina M. and Kardanova, Madina A.},
title = {Preeclampsia: the role of the terminal complement pathway in early diagnosis and targeted therapy: a review},
journal = {V.F.Snegirev Archives of Obstetrics and Gynecology},
year = {2026},
volume = {13},
number = {3},
pages = {238--247},
doi = {10.17816/aog708385}
}
EUVIMED